Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.83 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.81 |
| ▸ | CLK2 | P49760 | 1/20 | 0.81 |
| ▸ | BLK | P51451 | 1/20 | 0.81 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.81 |
| ▸ | STK3 | Q13188 | 1/20 | 0.81 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.81 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.81 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876943 | 0.92 | ROCK2 (0.81) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL882719 | 0.92 | ROCK2 (0.83) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877914 | 0.92 | ROCK2 (0.84) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL1722020 | 0.91 | ROCK2 (0.83) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877252 | 0.91 | ROCK2 (0.80) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877108 | 0.91 | ROCK2 (0.80) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877239 | 0.91 | ROCK2 (0.87) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL30743053 | 0.91 | ROCK2 (0.87) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL878209 | 0.91 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL3791531 | 0.90 | ROCK2 (0.82) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | claimed |
| EP-1865958-B1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2015-07-08 | — | — | EP | claimed |
| US-8916576-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-8357693-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2013-01-22 | — | — | US | claimed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | claimed |
| EP-2406236-A1 | RHO KINASE INHIBITORS | Surface Logix, Inc. (US) | 2012-01-18 | — | — | EP | claimed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | claimed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | claimed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | claimed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | ROCK2 1/4885ROCK1 4/4885CLK2 337/4885 |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885CLK2 1806/4885 |
| US-20120202793-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.